ArticleCell death & disease2025
CARM1 S217 phosphorylation by CDK1 in late G2 phase facilitates mitotic entry.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- An Integrated Cellular Computational Pipeline Decodes Luteolin to Design Possible Allosteric CDK1/CYCLIN B1 Inhibitors That Overcome Breast Cancer Stemness.Pharmaceuticals (Basel, Switzerland) · 2026Article
- KDM4A Erases the H3R17me2a Mark, Facilitating Chromosome Condensation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities.Journal of biomedical science · 2026Review
- Reversible arginine methylation regulates mitochondrial IDH2 activity: coordinated control by CARM1 and KDM3A/4A.Cell death & disease · 2026Article
- Context-specific applications of CARM1 inhibitors: functional profiles of EZM2302 and TP-064.Molecular medicine (Cambridge, Mass.) · 2025Article
- Reversible arginine methylation of PI3KC2α controls mitotic spindle dynamics.Cell communication and signaling : CCS · 2025Article
- Multifaceted roles of CARM1 beyond histone arginine methylation.Experimental & molecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The coactivator-associated arginine methyltransferase 1 (CARM1) functions as an epigenetic writer, however, its role in mitosis remains poorly understood. In this study, we identified CARM1 as a novel substrate of cyclin-dependent kinase 1 (CDK1) and revealed its novel function as a scaffold that regulates CDK1 stability. During interphase, CARM1 acts as an adaptor in the Cullin-1-mediated CDK1 degradation process, limiting nuclear levels of CDK1. In late G2 phase, the CDK1/Cyclin B1 complex translocates to the nucleus, where it phosphorylates the S217 residue of CARM1. This phosphorylation not only inhibits CARM1's enzymatic activity but also facilitates its translocation to the cytoplasm, leading to the loss of its scaffolding function. Consequently, the CDK1/Cyclin B1 complex resides for longer in the nucleus and initiates mitosis. In addition, depletion or inhibition of CARM1 facilitates entry into mitosis, resulting in accelerated cell growth. Overall, our findings expand the cellular functions of CARM1 beyond its enzymatic activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.